The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation

Genes and Development

Volumn 30, Issue 7, 2016, Pages 786-797

  Aylon, Yael ^a   Gershoni, Anat ^a   Rotkopf, Ron ^a   Biton, Inbal E ^a   Porat, Ziv ^a   Koh, Anna P ^b   Sun, Xiaochen ^b   Lee, Youngmin ^b   Fiel, Maria Isabel ^b   Hoshida, Yujin ^b   Friedman, Scott L ^b   Johnson, Randy L ^c   Oren, Moshe ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cholesterol; Fatty liver; Hippo; Lats; P53; YAP

Indexed keywords

CHOLESTEROL; LATS2 PROTEIN; PROTEIN P53; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; YAP PROTEIN; CHOLESTEROL INTAKE; LATS2 PROTEIN, HUMAN; LATS2 PROTEIN, MOUSE; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL FRACTIONATION; CHOLESTEROL INTAKE; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DOWN REGULATION; FATTY LIVER; FIBROSIS; GENE EXPRESSION; GENOTYPE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LIPID HOMEOSTASIS; LIVER CELL; LIVER CELL DAMAGE; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; HOMEOSTASIS; KNOCKOUT MOUSE; LIVER; METABOLISM; PHARMACOLOGY;

ANIMALS; CHOLESTEROL, DIETARY; FATTY LIVER; GENE DELETION; GENE EXPRESSION REGULATION; HEP G2 CELLS; HOMEOSTASIS; HUMANS; LIVER; MICE, KNOCKOUT; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84962449973     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.274167.115     Document Type: Article

References (51)

1. Ahrens M, Ammerpohl O, von Schonfels W, Kolarova J, Bens S, Itzel T, Teufel A, Herrmann A, Brosch M, Hinrichsen H, et al. 2013. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18: 296-302.
2. Albanis E, Friedman SL. 2001. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 5: 315-334.
3. Amaral JD, Castro RE, Steer CJ, Rodrigues CM. 2009. p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis. Trends Mol Med 15: 531-541.
4. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. 2006. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 20: 2687-2700.
5. Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, Oren M. 2009. Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene 28: 4469-4479.
6. Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X, Oren M. 2010. The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev 24: 2420-2429.
7. Aylon Y, Sarver A, Tovy A, Ainbinder E, Oren M. 2014. Lats2 is critical for the pluripotency and proper differentiation of stem cells. Cell Death Differ 21: 624-633.
8. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, McClatchey AI. 2010. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 24: 1718-1730.
9. Brown MS, Goldstein JL. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340.
10. Caballero F, Fernandez A, De Lacy AM, Fernandez-Checa JC, Caballeria J, Garcia-Ruiz C. 2009. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 50: 789-796.
11. Charni M, Rivlin N, Molchadsky A, Aloni-Grinstein R, Rotter V. 2014. p53 in liver pathologies—taking the good with the bad. J Mol Med (Berl) 92: 1229-1234.
12. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al. 2011. Role of YAP/TAZ in mechanotransduction. Nature 474: 179-183.
13. Fausto N, Campbell JS. 2003. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 120: 117-130.
14. Fiel MI, Antonio LB, Nalesnik MA, Thung SN, Gerber MA. 1997. Characterization of ductular hepatocytes in primary liver allograft failure. Mod Pathol 10: 348-353.
15. Gouw AS, Clouston AD, Theise ND. 2011. Ductular reactions in human liver: diversity at the interface. Hepatology 54: 1853-1863.
16. Guicciardi ME, Gores GJ. 2005. Apoptosis: a mechanism of acute and chronic liver injury. Gut 54: 1024-1033.
17. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. 1998. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory elementbinding protein-2. J Clin Invest 101: 2331-2339.
18. Horton JD, Goldstein JL, Brown MS. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125-1131.
19. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci 100: 12027-12032.
20. Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, Wang X. 1993. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci 90: 11603-11607.
21. Ioannou GN, Morrow OB, Connole ML, Lee SP. 2009. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 50: 175-184.
22. Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, Li W, Miyagi T, Hosui A, Tatsumi T, et al. 2011. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 121: 3343-3356.
23. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L, Lowe SW. 2008. Senescence of activated stellate cells limits liver fibrosis. Cell 134: 657-667.
24. Lee RG, Tsamandas AC, Demetris AJ. 1997. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 26: 1415-1422.
25. Lee YA, Wallace MC, Friedman SL. 2015. Pathobiology of liver fibrosis: a translational success story. Gut 64: 830-841.
26. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, et al. 2011. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13: 376-388.
27. Li J, Chen X, Ding X, Cheng Y, Zhao B, Lai ZC, Al Hezaimi K, Hakem R, Guan KL, Wang CY. 2013. LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction. Cell Rep 5: 1650-1663.
28. Lopez-Vicario C, Gonzalez-Periz A, Rius B, Moran-Salvador E, Garcia-Alonso V, Lozano JJ, Bataller R, Cofan M, Kang JX, Arroyo V, et al. 2014. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut 63: 344-355.
29. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, et al. 2010. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci 107: 1437-1442.
30. Menendez JA, Lupu R. 2007. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777.
31. Moroishi T, Hansen CG, Guan KL. 2015. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15: 73-79.
32. Moylan CA, Pang H, Dellinger A, Suzuki A, Garrett ME, Guy CD, Murphy SK, Ashley-Koch AE, Choi SS, Michelotti GA, et al. 2014. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 59: 471-482.
33. Okamoto H, Mizuno K, Horio T. 2003. Monocyte-derived multinucleated giant cells and sarcoidosis. J Dermatol Sci 31: 119-128.
34. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. 2008. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 19: 65-73.
35. Sakai J, Duncan EA, Rawson RB, Hua X, Brown MS, Goldstein JL. 1996. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 85: 1037-1046.
36. Shao W, Espenshade PJ. 2012. Expanding roles for SREBP in metabolism. Cell Metab 16: 414-419.
37. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al. 2014. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 16: 357-366.
38. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550.
39. Swinnen JV, Brusselmans K, Verhoeven G. 2006. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9: 358-365.
40. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S. 2005. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11: 1380-1385.
41. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC. 2011. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141: 1393-1403.
42. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
43. Visser S, Yang X. 2010. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 9: 3892-3903.
44. Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Grompe M. 2003. The origin and liver repopulating capacity of murine oval cells. Proc Natl Acad Sci 100: 11881-11888.
45. Wang X, Zhao X, Gao X, Mei Y, Wu M. 2013. A new role of p53 in regulating lipid metabolism. J Mol Cell Biol 5: 147-150.
46. Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, Zhang X, Zhang F, Chen H, Liu Y, et al. 2014. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci 111: E89-E98.
47. Yahagi N, Shimano H, Matsuzaka T, Najima Y, Sekiya M, Nakagawa Y, Ide T, Tomita S, Okazaki H, Tamura Y, et al. 2003. p53 Activation in adipocytes of obese mice. J Biol Chem 278: 25395-25400.
48. Ye J, DeBose-Boyd RA. 2011. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol 3.
49. Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe- Mooney B, Gurung B, Shrestha K, Cahan P, Stanger BZ, Camargo FD. 2014. Hippo pathway activity influences liver cell fate. Cell 157: 1324-1338.
50. Yimlamai D, Fowl BH, Camargo FD. 2015. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol 63: 1491-1501.
51. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, et al. 2009. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16: 425-438.